- Staying on the antisense theme, Hybridon presented data at the conference which imply that its GEM 91 oligonucleotide has multiple actions in preventing HIV replication and may offer limited potential for resistance formation. Randal Byrn of Harvard Medical School and Deaconess Hospital in the USA told the meeting that GEM 91 showed potent inhibition of acute infection of cells by HIV-1, blocked attachment to cells, inhibited the production of viral DNA and caused a reduction in gag mRNA levels in infected cells. GEM 91 is currently in Phase I/II trials (Marketletter July 1).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze